Overview

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Status:
Terminated
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the safety of zalutumumab in combination with radiotherapy as the treatment of patients with head and neck cancer who are not eligible for platinum based chemotherapy.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genmab
Treatments:
Antibodies, Monoclonal
Zalutumumab